EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV

Nicole Lioufas, Alan Street, Paul Champion De Crespigny, Stephen G. Holt

Journal of Renal and Hepatic Disorders · 2018

DOI: 10.15586/jrenhep.2018.33 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Renal and Hepatic Disorders, 2018. Verfasst von Nicole Lioufas und 3 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tenofovir disoproxil fumarate (TDF) is a common antiretroviral utilised in the treatment of human immunodeficiency virus (HIV) and hepatitis B infections. It is associated with the development of tubulotoxicity and tubulopathies, and is not recommended in the treatment of patients with baseline chronic kidney disease. Until now, guidelines have suggested frequent monitoring of serum biochemistry to detect the development of such complications. In recent trials, a new prodrug formulation of tenofovir alafenamide (TAF) has been shown to exhibit less tubular toxicity than its counterpart due to a lower serum concentration of its metabolites. In this article, we share our experience with two patients who developed tubulotoxicity following the commencement of TDF-based regimens in HIV, and its improvement following its change to TAF, and review the available literature regarding tenofovir-based nephrotoxicity.

Zitieren

APA

Lioufas, N., Street, A., Crespigny, P. C. D., & Holt, S. G. (2018). Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV. Journal of Renal and Hepatic Disorders. https://doi.org/10.15586/jrenhep.2018.33

Vancouver

Lioufas N, Street A, Crespigny PCD, Holt SG. Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV. Journal of Renal and Hepatic Disorders. 2018. doi:10.15586/jrenhep.2018.33

BibTeX
@article{Lioufas2018,
  author = {Lioufas, Nicole and Street, Alan and Crespigny, Paul Champion De and Holt, Stephen G.},
  title = {Monitoring the Effects of Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide Switch for Tubulotoxicity in Highly Treatment-Experienced or in Very Sick Individuals Infected with HIV},
  journal = {Journal of Renal and Hepatic Disorders},
  year = {2018},
  doi = {10.15586/jrenhep.2018.33}
}
Kostenlos starten →